Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema
-
Published:2023-05
Issue:5
Volume:7
Page:413-419
-
ISSN:2468-6530
-
Container-title:Ophthalmology Retina
-
language:en
-
Short-container-title:Ophthalmology Retina
Author:
Patel Nimesh A.ORCID,
Al-Khersan HaseninORCID,
Yannuzzi Nicolas A.,
Lin JamesORCID,
Smiddy William E.ORCID
Reference6 articles.
1. Variation in use and content of prescription drug step therapy protocols, within and across health plans;Lenahan;Health Aff (Millwood),2021
2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials;Wykoff;Lancet,2022
3. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial;Wells;Ophthalmology,2016
4. Aflibercept monotherapy or bevacizumab first for diabetic macular edema;Jhaveri;N Engl J Med,2022
5. A cost-effectiveness analysis of intravitreal aflibercept for the prevention of progressive diabetic retinopathy;Patel;Ophthalmol Retina,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献